Currently out of the existing stock ratings of Matthew Harrison, 433 are a HOLD (37.78%), 628 are a BUY (54.8%), 85 are a SELL (7.42%).
Analyst Matthew Harrison, currently employed at MORGAN STANLEY, has had 61.81% of price targets met with an average potential upside of 30.31%, reached in 318 days on average.
Matthew Harrison has documented 2,191 price targets and ratings displayed on 103 stocks. The coverage is on Healthcare, Technology, Basic Materials, Energy, Industrials, Consumer Cyclical, Communication Services sectors.
Most recent stock forecast was given on BMRN, Biomarin Pharmaceutical.
Analyst best performing recommendations are on CMRX (CHIMERIX).
The best stock recommendation documented was for CMRX (CHIMERIX) on 2/23/2016. The price target of $5 was fulfilled within 1 day with a profit of $0.54 (12.11%), with a performance score of 121.08.
Average potential price target upside
Analyst name
Rating
Current price target
Potential Upside
Previous price target
Date of last PT
Price targets met ratio
Average potential upside
Average Days to Hit Target
Performance score
Buy Since 28-Mar-2024
$5
$3.66 (273.13%)
$10
2 months 29 days ago
(17-Aug-2026)
0/5 (0%)
$3.9 (354.55%)
Buy Since 26-Apr-2021
$8
5 months 7 days ago
(08-Jun-2026)
1/15 (6.67%)
$4.24 (112.77%)
70
Buy Since 04-Dec-2025
$2
$0.66 (49.25%)
$6
5 months 11 days ago
(04-Jun-2026)
0/4 (0%)
$0.68 (51.52%)
Buy Since 13-Mar-2024
$9
$7.66 (571.64%)
$13
8 months 12 days ago
(03-Mar-2026)
0/2 (0%)
$4.95 (122.22%)
Buy Since 10-May-2022
$5
$3.98 (390.20%)
$8
1 years 4 months 26 days ago
(20-Jun-2025)
0/13 (0%)
$2.23 (80.51%)
Which stock is Matthew Harrison most bullish on?
Which stock is Matthew Harrison most reserved on?
What Year was the first public recommendation made by Matthew Harrison?
